Karyopharm receives fda fast track designation for selinexor for the treatment of myelofibrosis

– regulatory designation includes primary myelofibrosis, post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis – – pivotal phase 3 study of selinexor and ruxolitinib in treatment-naÏve myelofibrosis initiated in june 2023 – newton, mass. , july 17, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the united states food and drug administration (fda) has granted fast track designation to the development program of selinexor for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis.
KPTI Ratings Summary
KPTI Quant Ranking